[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20071655L - Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep - Google Patents

Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep

Info

Publication number
NO20071655L
NO20071655L NO20071655A NO20071655A NO20071655L NO 20071655 L NO20071655 L NO 20071655L NO 20071655 A NO20071655 A NO 20071655A NO 20071655 A NO20071655 A NO 20071655A NO 20071655 L NO20071655 L NO 20071655L
Authority
NO
Norway
Prior art keywords
lidocaine
targeted delivery
treating cough
nebulized
local anesthetics
Prior art date
Application number
NO20071655A
Other languages
English (en)
Norwegian (no)
Inventor
Alan Bruce Montgomery
Thomas Hofmann
Kevin Stapleton
Original Assignee
Corus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corus Pharma Inc filed Critical Corus Pharma Inc
Publication of NO20071655L publication Critical patent/NO20071655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20071655A 2004-09-20 2007-03-29 Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep NO20071655L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61165604P 2004-09-20 2004-09-20
US63502204P 2004-12-09 2004-12-09
PCT/US2005/002555 WO2006036180A1 (en) 2004-09-20 2005-01-28 Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks

Publications (1)

Publication Number Publication Date
NO20071655L true NO20071655L (no) 2007-06-19

Family

ID=36119205

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20071655A NO20071655L (no) 2004-09-20 2007-03-29 Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep
NO20071654A NO20071654L (no) 2004-09-20 2007-03-29 Fremgangsmate for a forbedre toleransen for terapeutiske effektive midler levert ved inhalering

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20071654A NO20071654L (no) 2004-09-20 2007-03-29 Fremgangsmate for a forbedre toleransen for terapeutiske effektive midler levert ved inhalering

Country Status (7)

Country Link
US (1) US20060062739A1 (ja)
EP (1) EP1796637A4 (ja)
JP (2) JP2008513444A (ja)
AU (1) AU2005290312A1 (ja)
CA (1) CA2581209A1 (ja)
NO (2) NO20071655L (ja)
WO (2) WO2006036180A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824466A4 (en) * 2004-12-16 2008-03-05 Advanced Inhalation Res Inc COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS
EP2101819B1 (en) 2006-11-20 2013-01-09 President and Fellows of Harvard College Methods, compositions, and kits for treating pain and pruritis
JP2008259704A (ja) * 2007-04-12 2008-10-30 Hisamitsu Pharmaceut Co Inc プレフィルド型シリンジ
CA2703019A1 (en) 2007-09-20 2009-03-26 University Of Rochester Method and compositions for treatment or prevention of inflammatory conditions
PT2410981T (pt) * 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
CN102725401A (zh) 2009-07-10 2012-10-10 哈佛大学校长及研究员协会 作为抗炎药的永久带电荷的钠和钙通道阻断剂
EP3331609A4 (en) 2015-08-03 2019-03-27 President and Fellows of Harvard College LOADED ION CHANNEL BLOCKS AND METHOD OF USE
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
EP3938345A4 (en) 2019-03-11 2023-01-18 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
WO2020185881A1 (en) 2019-03-11 2020-09-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MX2021012723A (es) * 2019-04-18 2022-01-31 Jon Greenfield Inhalador de presión positiva para entrega de medicamento inhalable y métodos para uso.
EP4054586A4 (en) 2019-11-06 2023-11-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3155586A1 (en) 2019-11-06 2021-05-14 Bridget M. Cole Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN115279731B (zh) 2020-03-11 2024-09-13 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
CN111632024B (zh) * 2020-07-02 2021-12-31 渠静 一种局麻药制剂及其制备方法、应用
AU2021400335A1 (en) 2020-12-17 2023-06-22 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
CA2334481A1 (en) * 1998-06-09 1999-12-16 Nortran Pharmaceuticals Inc. Compositions and methods for treatment of cough
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
CA2414389A1 (en) * 2000-06-23 2002-01-03 Mayo Foundation For Medical Education & Research Methods of treating neutrophil-related diseases with topical anesthetics
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
WO2003072080A1 (en) * 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release

Also Published As

Publication number Publication date
JP2008513444A (ja) 2008-05-01
AU2005290312A1 (en) 2006-04-06
US20060062739A1 (en) 2006-03-23
JP2008513445A (ja) 2008-05-01
WO2006036181A1 (en) 2006-04-06
NO20071654L (no) 2007-06-19
EP1796637A1 (en) 2007-06-20
WO2006036180A1 (en) 2006-04-06
EP1796637A4 (en) 2010-01-13
CA2581209A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
NO20071655L (no) Malrettet levering av lidocaine og andre lokale bedovelsesmidler og en fremgangsmate for behandling av hoste og tussivangrep
Wilson et al. Airborne transmission of severe acute respiratory syndrome coronavirus‐2 to healthcare workers: a narrative review
Sheng et al. HIV/AIDS epidemiology and prevention in China
Wang et al. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase
Afshan et al. Is there a role of a small dose of propofol in the treatment of laryngeal spasm?
MEP30208A (en) Pressurised metered dose inhalers containing solutions of beta-2 agonists
RU2016101054A (ru) Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем
Kashyap et al. Withania somnifera as a potential future drug molecule for COVID-19
WO2006102345A3 (en) Methods and systems for operating an aerosol generator
Boyd et al. Serious overdoses involving buprenorphine in Helsinki
WO2007047372A3 (en) Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
US20100196285A1 (en) Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract
WO2006060027A3 (en) A method for improvement of tolerance for therapeutically effective agents delivered by inhalation
NO20044001L (no) Aerosolformulering for inhalasjon omfattende et tiotropiumsalt
Cork et al. Justification for Chest Physiotherapy during Ultra‐Protective Lung Ventilation and Extra‐Corporeal Membrane Oxygenation: A Case Study
Lema et al. Evidence-based perioperative management of a child with upper respiratory tract infections (URTIs) undergoing elective surgery; A systematic review
Cook et al. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism
Wahl et al. New medical management techniques for acute exacerbations of chronic rhinosinusitis
Elcock et al. Sevoflurane vs. isoflurane: a clinical comparison in day surgery
WO2021258086A3 (en) Gallium in the treatent of coronavirus disease
WO2005107768A3 (en) Method for improving ventilatory efficiency
CN102266344A (zh) 一种用于治疗呼吸障碍的药物组合物
Shu et al. Efficacy and Safety of Re Du Ning Injection for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐Analysis
Farshchi et al. Antinociceptive and antiinflammatory effects of Teucrium hyrcanicum aqueous extract in male mice and rats
DK202170549A1 (en) Medicament for inhalation or breathing, and inhaler or breathing device comprising same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application